Targeting CLPTM1L for treatment and prevention of cancer

Patent metadata

Field	Value
Publication number	US-10266586-B2
Application number	US-201515111445-A
Country	US
Kind code	B2
Filing date	Jan 6, 2015
Priority date	Jan 14, 2014
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).

First claim

I claim:

1. A CLPTM1L-targeting agent, wherein the CLPTM1L-targeting agent is a monoclonal antibody specific for at least a portion of a CLPTM1L polypeptide and selected from anti-CLPTM1L monoclonal antibody clones 6-1 (ATCC PTA-125531), 10-2 (ATCC PTA-125532), and 10-3(ATCC PTA-125530).

2. A pharmaceutical composition comprising the CLPTM1L-targeting agent of claim 1 and a pharmaceutically acceptable carrier.

3. An article of manufacture comprising: (a) the pharmaceutical composition of claim 2 , and (b) an insert providing instructions for treating a solid tumor in a human subject.

4. A method for treating a lung cancer comprising administering a therapeutically effective amount of a compound comprising a CLPTM1L-targeting agent to a subject in need thereof, wherein the CLPTM1L-targeting agent is a monoclonal antibody specific for at least a portion of a CLPTM1L polypeptide and selected from anti-CLPTM1L monoclonal antibody clones 6-1 (ATCC PTA-125531), 10-2 (ATCC PTA-125532), and 10-3 (ATCC PTA-125530), whereby the lung cancer is treated in the subject.

5. The method of claim 4 , wherein the subject is a human.

6. The method of claim 4 , wherein the lung cancer exhibits resistance to a chemotherapeutic agent.

7. The method of claim 6 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, gemcitabine, carboplatin, carmustine, methotrexate, fluorouracil, goserelin, leuprolide, tamoxifen, docetaxel, paclitaxel, aldesleukin, interleukin-2, etoposide (VP-16), interferon-alpha, tretinoin (ATRA), bleomycin, dactinomycin, daunorubicin, doxorubicin, mitomycin, vinblastine, and vincristine.

8. The method of claim 4 , wherein the compound is administered with a pharmaceutically acceptable carrier.

Assignees

• Medical College Wisconsin Inc

Inventors

• James Michael A

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K16/3046

  Stomach, Intestines · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title